Systems Medicine and Integrated Care to Combat Chronic Noncommunicable Diseases by Bousquet, Jean et al.
Non-communicable diseases, the major global 
health problem of the century
Chronic diseases are disorders of long duration and 
generally slow progression [1]. They include four major 
non-communicable diseases (NCDs) listed by the World 
Health Organization (WHO) [2] – cardiovascular 
diseases, cancer, chronic respiratory diseases and 
diabetes – as well as other NCDs, such as 
neuropsychiatric disorders [3] and arthritis. As survival 
rates have improved for infectious and genetic diseases, 
chronic diseases have come to include communicable 
diseases (such as HIV/AIDS) and genetic disorders (such 
as cystic fibrosis). NCDs represent the major global 
health problem of the 21st century [4,5]; they affect all 
age groups [6] and their burden is greater than that of 
infectious diseases. NCDs are the world leading cause of 
disease burden and mortality [2] and are increasing in 
prevalence and burden [7], even in low- and middle-
income countries [8]. Costs incurred by uncontrolled 
NCDs are substantial, especially in underserved 
populations [9] and low- and middle-income countries 
[10,11]. NCDs are an under-appreciated cause of poverty 
and hinder economic development [11]. Importantly, 
management of NCDs has recently been prioritized 
globally (Box 1).
Chronic diseases are caused by complex gene-
environment interactions acting across the lifespan from 
the fetus to old age (Figure 1). In this context, 
‘environment’ includes risk and protective factors 
associated with environment and lifestyle, such as 
Abstract
We propose an innovative, integrated, cost-effective 
health system to combat major non-communicable 
diseases (NCDs), including cardiovascular, chronic 
respiratory, metabolic, rheumatologic and neurologic 
disorders and cancers, which together are the predominant 
health problem of the 21st century. This proposed holistic 
strategy involves comprehensive patient-centered 
integrated care and multi-scale, multi-modal and multi-
level systems approaches to tackle NCDs as a common 
group of diseases. Rather than studying each disease 
individually, it will take into account their intertwined 
gene-environment, socio-economic interactions 
and co-morbidities that lead to individual-specific 
complex phenotypes. It will implement a road map for 
predictive, preventive, personalized and participatory (P4) 
medicine based on a robust and extensive knowledge 
management infrastructure that contains individual 
patient information. It will be supported by strategic 
partnerships involving all stakeholders, including general 
practitioners associated with patient-centered care. This 
systems medicine strategy, which will take a holistic 
approach to disease, is designed to allow the results to 
be used globally, taking into account the needs and 
specificities of local economies and health systems.
Systems medicine and integrated care to combat 
chronic noncommunicable diseases
Jean Bousquet1*, Josep M Anto2, Peter J Sterk3, Ian M Adcock4, Kian Fan Chung5, Josep Roca6, Alvar Agusti6, Chris Brightling7, 
Anne Cambon-Thomsen8, Alfredo Cesario9, Sonia Abdelhak10, Stylianos E Antonarakis11, Antoine Avignon12, Andrea Ballabio13, 
Eugenio Baraldi14, Alexander Baranov15, Thomas Bieber16, Joël Bockaert17, Samir Brahmachari18, Christian Brambilla19, Jacques 
Bringer20, Michel Dauzat21, Ingemar Ernberg22, Leonardo Fabbri23, Philippe Froguel24, David Galas25, Takashi Gojobori26, Peter 
Hunter27, Christian Jorgensen28, Francine Kauffmann29, Philippe Kourilsky30, Marek L Kowalski31, Doron Lancet32, Claude Le 
Pen33, Jacques Mallet34, Bongani Mayosi35, Jacques Mercier36, Andres Metspalu37, Joseph H Nadeau25, Grégory Ninot38, Denis 
Noble39, Mehmet Öztürk40, Susanna Palkonen41, Christian Préfaut36, Klaus Rabe42, Eric Renard20, Richard G Roberts43, Boleslav 
Samolinski44, Holger J Schünemann45, Hans-Uwe Simon46, Marcelo Bento Soares47, Giulio Superti-Furga48, Jesper Tegner49, 
Sergio Verjovski-Almeida50, Peter Wellstead51, Olaf Wolkenhauer52, Emiel Wouters53, Rudi Balling54, Anthony J Brookes55, 
Dominique Charron56, Christophe Pison57,58, Zhu Chen59, Leroy Hood25 and Charles Auffray56,57,58,60,61
CORRESPONDENCE Open Access
*Correspondence: jean.bousquet@inserm.fr
1Department of Respiratory Diseases, Arnaud de Villeneuve Hospital, 
CHU Montpellier, INSERM CESP U1018, Villejuif, France 
Full list of author information is available at the end of the article
Bousquet et al. Genome Medicine 2011, 3:43 
http://genomemedicine.com/content/3/7/43
© 2011 Bousquet et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
tobacco, nutrition, indoor and outdoor air pollution and 
sedentary life [2].
Socio-economic determinants are intertwined with the 
onset, progression, severity and control of NCDs. There 
are functional interdependencies between molecular 
components, reflecting complex network perturbations 
that link cells, tissues and organs [12]. Early life events 
are crucial in the generation of NCDs, and aging 
increases disease complexity, adding, for example, tissue 
and cell senescence [13]. Comorbidity refers to the co-
existence of two or more diseases or conditions in the 
same individual that have similar risk factors and/or 
mechanisms. Most people with NCDs suffer from two or 
more diseases [14]. Co-morbidity and multi-morbidity 
are common signatures of NCDs and are associated with 
worse health outcomes [15], complex pharmacological 
interventions and clinical management, and increased 
healthcare costs [16]. However, little is known about how 
NCDs truly cluster at the genetic, molecular or 
mechanistic levels, and there is scant understanding of 
Box 1: Priorities for the prevention and control of NCDs
May 2008: 61st World Health Assembly. WHO recommended 
a worldwide priority policy on NCD prevention and control 
(2008 to 2013), including cardiovascular disease, cancer, chronic 
respiratory diseases [101] and diabetes, not least because they 
often have common environmental risk factors [2].
May 2010: United Nations (UN) General Assembly unanimously 
adopted Resolution A/RES/64/265: ’Tackling NCDs constitutes 
one of the major challenges for sustainable development in the 
21st century‘ [102].
December 2010: the Council of the European Union adopted 
conclusions based on innovative and global approaches for 
NCDs in public health and healthcare systems to further develop 
population-based and patient-centered policies [1].
2010: US Center for Disease Control and Prevention (CDC) [103] 
says that ’an essential strategy for keeping older adults healthy is 
preventing NCDs and reducing associated complications’.
19 September 2011: UN General Assembly symposium on NCDs.
Figure 1. NCDs are associated with complex gene-environment interactions modulated by socio-economic determinants, psychological 
factors, age and gender. The products of these interactions lead to the biological expression of NCDs and further to their clinical expression with 
co-morbidities. A new definition of NCD phenotypes is needed to understand how a network of molecular and environmental factors can lead to 
complex clinical outcomes of NCDs for prevention and control.
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how specific combinations of NCDs influence prognosis 
and treatment [16].
NCDs are multi-factorial. In addition to environmental 
factors and increased life expectancy, intrinsic host 
responses, such as local and systemic inflammation, 
immune responses and remodeling [17], have key roles in 
the initiation and persistence of diseases and co-
morbidities. The recent increase in NCDs has been 
associated in part with biodiversity loss [18], socio-
economic inequities linked with climate change, and loss 
of natural environments [19]. A more comprehensive 
understanding of these links will make it possible to 
propose more effective primary prevention strategies. 
The in utero environment is an important determinant of 
adult NCDs, including diabetes [20], coronary heart 
diseases [21], and asthma [22] or chronic obstructive 
pulmonary disease (COPD) [23]. Mechanistic links have 
been proposed that involve fetal expression of genes that 
are conserved across species, epigenetic mechanisms 
[22,24], early and maternal life infections, and/or 
environmental exposures. These need to be understood 
better [25], as early interventions may have the potential 
to reduce NCD burden [26].
Nutrition is a key determinant of health and NCDs. 
Understanding the underlying complexities of metabolic 
responses and pathophysiology is needed. Loss of 
biodiversity in food organisms causes micronutrient and 
vitamin deficiencies, and obesity and related chronic and 
degenerative diseases are a formidable challenge [27]. 
Nutritional intervention in early childhood may help 
prevent autoimmune diseases [28], and adoption and 
adherence to healthy diet recommendations are needed 
globally to prevent the onset and facilitate control of 
NCDs [29]. However, trying to change lifestyles using 
public health efforts remains a major challenge, and an 
interdisciplinary social and behavioral approach, 
including the cultural aspects of nutrition, is needed [30]. 
Tobacco use [31], biomass fuel combustion and air 
pollution [32] are among the major risk factors for NCDs; 
these act as early as in utero and in early life. Those 
working on the global prevention and control of NCDs 
should consider these risk factors because translational 
epidemiology is the key to exploring their role in the 
development of NCDs and to devising approaches that 
will enable successful guided interventions [33].
The development of a society, rich or poor, can be 
judged by the health of its population, how equitably 
health is distributed across the social spectrum, and the 
degree of protection provided to people who are 
disadvantaged by illness. Effective action against NCDs 
needs to include understanding of the social and 
economic determinants and their modification (Figure 1) 
[34]. Indeed, best-practice interventions targeted at 
coronary risk factors eliminate most socioeconomic 
differences that affect coronary heart disease mortality, 
and this should serve as an example to follow for other 
NCDs [35]. In May 2009, the 62nd WHO Assembly 
recommended re-orienting health systems globally to 
promote primary healthcare as the most cost-effective 
strategy [36]. Healthcare often focuses on single diseases, 
advanced technology, biomedical interventions and 
specialist care. Most healthcare takes place in primary 
care settings [37], with emphasis on providing a complete 
range of care, from home to hospital, and on investing 
resources rationally. Fragmenting care can reduce the 
ability of primary care clinicians to ensure that patient 
care is comprehensive, integrated, holistic, and 
coordinated [38], and to decide whether a person has a 
significant disease or temporary symptoms [39].
A proposal for multidisciplinary patient-centered 
management of chronic NCDs
We recommend that, to determine measures of disease 
severity and control, effective interventions and studies 
should be built around carefully phenotyped patients 
(Figure 2) and strictly follow carefully crafted 
methodological standards. Patients should be placed at 
the center of the system; if they are aware of and 
understand the resulting phenotype data, their health 
will benefit. We stress that patients must understand that 
it is their societal responsibility to make their anonymized 
data available to appropriate scientists and physicians so 
that the latter can create the predictive medicine of 
the future that will transform the health of their children 
and grandchildren. For patients to adopt this approach, 
it is essential that laws be passed protecting them 
against abuse of their personal data by insurance 
companies, health authorities or employers. This 
approach to patient-centeredness, if aided by community 
health teams, will advance research. It may also benefit 
from the experience gained in patient-centered medical 
homes [40,41].
The concepts of severity, activity, control and response 
to treatment are linked. Severity is the loss of function in 
the target organs induced by disease and may vary over 
time; as it may also vary with age, this needs to be 
regularly re-evaluated. Activity is the current level of 
activation of biological pathways causing the disease and 
the clinical consequences of this activation. Control is the 
degree to which therapeutic goals are being met [42]. 
Responsiveness is the ease with which control is achieved 
by therapy [43]. Control can be achieved using clinical 
and/or biological end points, such as glycemic control in 
diabetes [44]. Careful monitoring of co-factors, such as 
compliance, and of unavoidable risk factors is needed. 
The uniform definition of severe asthma presented to 
WHO is based on this approach [45] and therefore 
provides a model to assess NCD severity (Figure 3).
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Information and communication technologies (ICT) 
are needed for the implementation of integrated care in a 
systems medicine approach to enable prospective follow-
up of the patients. Home telemonitoring is promising 
[46] and should be explored further because continuous 
and precise monitoring makes each individual clinical 
history a valuable source of comprehensive information. 
More user-friendly and efficient ICT platforms are 
needed that include shared decision making, the process 
by which a healthcare choice is made jointly by the 
practitioner and the patient [47]. Ideally, an innovative 
patient management program would combine ICT, 
shared decision making and personalized education of 
the patient (and caregiver) about multidisciplinary 
approaches. The content, acceptance and effectiveness of 
such approaches should be tested to ensure that the 
autonomy, quality of life and capacity of patients are 
respected and enhanced, and that their values and 
preferences dominate decision making [48]. Practice-
based inter-professional collaborations is also key to 
improving healthcare processes and outcomes [49]. 
Qualitative assessment will provide insight into how 
interventions affect collaboration and how improved 
collaboration contributes to changes in outcomes.
Thus, we propose that NCD management should move 
towards holistic multi-modal integrated care, and 
Figure 2. Classical phenotypes are based on a priori ontologies (cardiovascular disease, chronic obstructive pulmonary disease (COPD) 
and type 2 diabetes), and new phenotypes are based on statistical modeling of all the complex components of NCD onset, persistence 
and prognosis.
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multi-scale, multi-level systems approaches. To reduce 
their socio-economic and public health impacts, we 
propose that NCDs should be considered as the 
expression of a continuum or common group of diseases 
with intertwined gene-environment, socio-economic 
interactions and co-morbidities that lead to complex 
phenotypes specific for each individual. The ‘systems 
medicine’ concept, which takes a holistic view of health 
and disease, encapsulates this perspective. Systems 
medicine aims to tackle all components of the complexity 
of NCDs so as to understand these various phenotypes 
and hence enable prevention (Box 2), control through 
health promotion [50] and personalized medicine [51], 
and an efficient use of health service resources [52]. It 
does this through integrated care using multidisciplinary 
and teamwork approaches centered in primary and 
community care [53], including the essential ethical 
dimension.
Systems biology and medical informatics for P4 
medicine of chronic NCDs
The main challenge regarding NCDs in the 21st century 
is to understand their complexity. Biology and medicine 
may be viewed as informational sciences requiring global 
systems methods using both hypothesis-driven and 
discovery-driven approaches. Systems medicine is the 
application of systems biology to medical research and 
practice [54,55]. Its objective is to integrate a variety of 
data at all relevant levels of cellular organization with 
clinical and patient-reported disease markers. It uses the 
power of computational and mathematical modeling to 
enable understanding of the mechanisms, prognosis, 
diagnosis and treatment of disease [56]. It involves a 
transition to predictive, preventive, personalized and 
participatory (P4) medicine, which is a shift from reactive 
to prospective medicine that extends far beyond what is 
usually covered by the term personalized medicine 
Figure 3. The concept of a uniform definition for NCD severity is based on control, responsiveness to treatment and risks (short, medium 
and long term). A single flow chart is proposed to define severity to improve phenotype characterization for all purposes (research, clinical and 
public health). It is based on diagnosis, therapeutic interventions and their availability/affordability, risk factors and co-morbidities.
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[57,58]. It incorporates patient and population 
preferences for interventions and health states by 
implementing effective societal actions [57] with an 
important public health dimension [59]. It is likely to be 
the foundation of global health in the future (Box 3).
Thus, there is an urgent need for development of 
information management systems that can enable secure 
storage of heterogeneous data, including clinical data, 
and provide tools for the management, search and 
sharing of the data. Such information needs to accessible, 
shared between investigators, queried, and integrated in 
a controlled and secure manner with molecular profiles 
and images obtained from high-throughput facilities. For 
example, one prediction arising from considerations of 
the evolution of P4 medicine suggests that, in 10 years or 
so, each patient will be surrounded by a virtual cloud of 
billions of data points; we will need information 
technology to reduce this staggering data dimensionality 
to simple hypotheses about health and disease for each 
individual patient [57].
A systems biology approach that is unbiased by old 
classification systems can be used to find new biomarkers 
of co-morbidities, disease severity and progression. In 
this approach, phenotypes of NCDs are analyzed in an 
integrative manner using mathematical and statistical 
modeling, taking all diseases into account, and 
embedding co-morbidities, severity and follow-up of the 
patients through analyses in dynamic models (Figure 4). 
Unknown phenotypes are defined and further analyzed 
using iterative cycles of modeling and experimental 
testing. Novel biomarkers are identified combining 
datasets from genomics, epigenetics, proteomics, 
transcriptomics, metabolomics and metagenomics. 
These new complex biomarkers will need to be validated 
and replicated in independent controls or prospective 
patient cohorts [60]. Using methods used in non-medical 
complex model systems, it should be possible to monitor 
‘early warning signals’, which predict the state of disease 
progression, and the occurrence of abrupt phase 
transitions (slowing down, increase in autocorrelation 
and variance) [61]. For example, in a mouse model of 
neurodegenerative disease, blood biomarkers have been 
shown to allow pre-symptomatic diagnosis and analysis 
of the stage of disease progression [62].
Modeling is a powerful tool for reducing the enormous 
complexity of comprehensive biological datasets to 
simple hypotheses. Modeling of the temporal behavior of 
disease read-outs at short [63] or long [64] intervals can 
identify sub-phenotypes of NCDs. Attempts to find novel 
biomarkers of disease development using a systems 
biology approach have been used to assess the 
mechanisms of severe asthma, allergy development [65] 
and cancer. One important role that biomarkers will have 
is to stratify a given disease into its different subtypes so 
that appropriate and distinct therapies can be selected for 
each subtype. Phenotypes can be modeled using 
statistical approaches, such as scale-free networks and 
Bayesian clustering models, that are based on the 
evaluation of NCDs as a whole, taking into account co-
morbidities, severity and follow-up. This approach will 
Box 2: Glossary of terms
The classical definition of prevention [101] includes:
• Primary prevention: to avoid the development of disease.
• Secondary prevention: recognize a disease before it results 
in morbidity (or co-morbidity).
• Tertiary prevention: to reduce the negative impact of 
established disease by restoring function and reducing 
disease-related complications.
Expanding on the traditional model of prevention, Gordon [104] 
proposed a three-tiered preventative intervention classification 
system on the basis of the population for whom the measure is 
advisable based on a cost-benefit analysis:
• Universal prevention addresses the entire population (for 
example, national, local community, school, and district) and 
aims to prevent or delay risk factor exposure. All individuals, 
without screening, are provided with information and skills 
necessary to prevent the problem.
• Selective prevention focuses on groups whose risk of 
developing problems is above average. The subgroups may 
be distinguished by characteristics such as age, gender, family 
history, or economic status.
• Indicated prevention involves a screening process.
According to these definitions, health promotion [50] should 
be used for primary universal and selective prevention strategies, 
whereas P4 medicine (predictive, preventive, personalized and 
participatory) [51] should be used for primary, secondary and 
tertiary indicated prevention strategies.
Box 3: Key expected benefits of P4 medicine
To prevent the occurrence of NCDs by implementing effective 
action at societal and individual levels:
• To detect and diagnose disease at an early stage, when it can 
be controlled effectively.
• To stratify patients into groups, enabling the selection of 
optimal therapy.
• To reduce adverse drug reactions through the predictive or 
early assessment of individual drug responses and assessing 
genes leading to ineffective drug metabolism.
• To improve the selection of new biochemical targets for drug 
discovery.
• To reduce the time, cost, and failure rate of clinical trials for 
new therapies.
• To shift the emphasis in medicine from reaction to prevention 
and from disease to wellness.
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make it possible to find intermediate phenotypes and 
patient-specific phenotypes. The challenge will be to 
develop efficient, automated and integrated workflows 
that predict the most suitable therapeutic strategy not 
only at the population level but, most importantly, at the 
individual patient level.
Bioinformatics, medical informatics and their interplay 
(sometimes termed biomedical informatics) will be key 
enablers in structuring, integrating and providing 
appropriate access to the enormous amount of relevant 
data and knowledge [66,67]. Medical informatics needs 
to provide ubiquitous and powerful electronic healthcare 
record technologies to securely aggregate and handle 
diverse, complex, and comprehensive data types [68]. 
Biomedical informatics must develop ways to use these 
content-rich electronic healthcare records to provide 
advanced decision support that considers all aspects of 
normal and disease biology, guided by clinically relevant 
insights and biomarker discovery research strategies 
[69,70]. Bioinformatics will need to constantly restructure 
and refine global data to distill the clinically useful 
elements and the derived models, so they can feed this 
information system in a real-time, automated fashion, 
constantly incorporating clinical expertise. P4 medicine 
is evolving so rapidly in its understanding of disease 
states that the individual patient’s data must continually 
be re-examined so that new insights into the health and 
disease state of the individual can be gained. This general 
informatics framework, based on an advanced ICT 
infrastructure, will provide the basis for empowering P4 
medicine.
Given the complexity of NCDs, bio-clinical scientific 
progress will depend critically on large-scale pooled 
analyses of high quality data from many biobanks [71] 
and bio-clinical studies (such as BioSHaRE-EU [72]). 
Biomedical informatics and knowledge management 
platforms have made significant advances towards 
enabling the development of technologies to organize 
molecular data at the level required for the complexity of 
NCD data [73,74]. Data analysis, integration and 
modeling require strict statistical procedures in order to 
avoid false discoveries [75]. They can be performed, for 
example, using the joint knowledge management 
platform of European Framework Program 7 (EU FP7) 
projects, including U-BIOPRED [76], MeDALL [65], 
AirPROM and SYNERGY-COPD, and using similar 
initiatives worldwide. Large-scale profiling to discover 
early markers of disease progression before the 
appearance of any symptoms has already been performed 
in a large prospective human cohort [77,78].
Complementary approaches using computational 
models that extend existing models derived from the 
Physiome project, including biomedical imaging, can be 
used together with statistical modeling of various types 
of clinical data to further define phenotypes and develop 
predictive models. These can be used within the 
framework of a fully integrated (preferably open source) 
knowledge management platform [79]. Such a platform 
for knowledge management, including annotation and 
ontologies, would then operate on top of the medical 
informatics infrastructure, setting the stage for a systems 
medicine approach to NCDs. In our collective experience 
these necessary aspects of medical informatics have a 
tendency to be overlooked in funding efforts targeting 
complex diseases.
Integrated care of chronic NCDs using P4 systems 
medicine
Integrated care, a core component of health and social 
care reforms, seeks to close the traditional gap between 
health and social care [80]. Population health sciences 
should integrate personalized medicine in public health 
interventions to prevent and manage NCDs in a cost-
effective manner by involving all stakeholders, including 
patients [81]. The objectives of this proposed integration 
Figure 4. Iterative mathematical modeling to increase 
knowledge on NCDs. Various targeted or comprehensive data 
types are collected from samples of individuals with carefully 
defined phenotypes, processed using probabilistic and network 
analysis tools, and integrated into predictive models using a 
knowledge management and simulation platform, leading to the 
refinement of the classification of NCDs. Mechanistic hypotheses 
and complex biomarkers of NCDs generated through this process 
are then tested and validated iteratively using small then large 
cohorts of independent samples, providing potential diagnostic and 
therapeutic solutions for the general population.
Prediction Analysistools
Probabilistic/
clustering/
network analysis
Data types
Validation/
model
iteration
All: Risk factors, phenotypes, clusters of NCDs
Selected extreme phenotype clusters: Genetics,
targeted proteomics, transcriptomics, epigenetics
Population health science
complex network
Feedback
solution
Validated biomarkers
for NCDs
Simulator
development
Modeling
clusters of NCDs
Integrative knowledge
management
Confirmation on a 
larger sample using
cohorts
Key:
Analysis
Sample
Data
Bousquet et al. Genome Medicine 2011, 3:43 
http://genomemedicine.com/content/3/7/43
Page 7 of 12
are: (i) to investigate questions related to NCDs; (ii) to 
improve the quality of primary care; and (iii) to widely 
disseminate new information that will improve overall 
health at both a local and national level [82]. Chronic 
diseases can disconnect individuals from their usual 
milieu, with negative implications for physical, social and 
mental well-being. Moving beyond the disease-by-
disease approach to tackle NCDs demands an improved 
understanding of NCD by patients, and a better 
understanding of their common causes. At the local 
level, strategies such as community oriented primary care 
can link and reinforce personal and public health 
efforts [83].
To understand, preserve and improve the health of 
human populations and individuals, an integrated 
research strategy should include all components of 
research on NCDs and be integrated for optimal patient 
management [84,85]. Careful evaluation is needed of: (i) 
the acceptance of multi-morbidity of NCDs by the 
patient, with particular attention to cultural and social 
barriers, gender and age; (ii) the engagement of patients 
in decisions regarding management [86], research and 
clinical trials [55,57]; and (iii) the improvement of quality 
of life that would result from the proposed management. 
Targeting NCDs and their comorbidities will directly 
affect healthy aging, which has been described as a 
‘keystone for a sustainable Europe’ [87]. Screening, early 
diagnosis, prevention and treatment of hidden 
comorbidities in patients with diagnosed NCDs will 
reduce their morbidity and increase healthy life years.
The direct and indirect costs of uncontrolled NCDs are 
substantial for the patient, the family and society, 
especially in underserved populations [9]. P4 medicine 
should be put into the context of health economics to 
show that expensive strategies are cost-effective [55,57]. 
Chronic diseases place a considerable economic burden 
on the society and increase inequities. The social 
dimension of NCDs needs to be pursued in the economic 
and employment fields. The net social benefit of 
improving medical and social care related to NCDs 
should take co-benefits into account. Health costs for 
NCDs should be balanced with health benefits, wealth 
creation and economic development. The management 
of NCDs requires the coordination of stakeholders in the 
public and private sectors within a governance 
framework that includes networks of care. Therefore, 
research should be done to identify social determinants 
and to create public health systems that translate efficacy 
into effectiveness in the community [88]. Moreover, 
strengthening health equity across nations and 
socioeconomic groups is needed to meet the ambitions 
of the Commission on Social Determinants of Health, 
who have proposed closing the health gap between 
nations and groups in a generation [89].
Values are the basis of most actions in health and the 
economy, and these values are often not made explicit. 
Changing paradigms and approaches to NCDs may 
challenge fundamental societal values and professional 
habits [59,90]. The apparent contradiction between the 
development of a more tailored medical approach to 
NCDs and the public health dimensions of their 
prevention and care needs to be addressed using a value-
based analysis. Thus, a thorough analysis of values 
underlying P4 medicine should be conducted in diverse 
contexts and should become part of the basis of decision-
making. The respective weight of the multiple 
stakeholders involved in the priority setting must be 
made clear, with transparency and proportionality as key 
features. P4 medicine development should be a global 
aim and not a privilege of ‘rich’ countries. Using data 
obtained from all components of research, guidelines on 
NCDs applicable to primary care could be developed 
using up-to-date methodology [91,92]. Policies for 
implementation could then be proposed, to translate the 
concept of NCD into practice. They should distribute the 
burdens equitably, also considering gender and age.
Multidisciplinary training of all stakeholders, with 
particular emphasis on the participation of patient 
associations, is a further essential component. Many 
health and non-health professionals need to be educated 
in the general approach to the research and management 
of patients with NCDs. Innovative training programs 
using ICT will be essential in this implementation. Such 
education will also need to address questions of how to 
teach the subject and how people learn it, rather than 
merely regarding education as a process of transmission 
and transaction for everyone involved. This includes 
taking into account points of view, habits of mind, and all 
the information requested for the needs of the strategy. 
The educational program needs to forge educational 
systems to help participants think in a coherent way 
about NCDs. A module of the program should be 
developed around patient feedback to help them be 
engaged in all aspects of NCDs, including research.
Many patients with NCDs live in developing countries 
where medications and services are often unavailable or 
inaccessible. Effective medications, such as inhaled 
corticosteroids for asthma [93] or insulin for diabetes, 
should be made available for all patients [94]. In addition, 
there should be a global cost-effective application of P4 
medicine across the world [95]. It is likely that genomic 
applications and ICT will become available to many 
developing countries at a relatively low cost in the next 
few years. In addition, new private-public strategic 
partnerships, such as the pre-competitive Innovative 
Medicines Initiative, a joint undertaking of the European 
Union and the European Federation of Pharmaceutical 
Industry Associations [96], and the Program on 
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Public-Private Partnerships of the United States National 
Institutes of Health Roadmap [97], are required to 
overcome the bottlenecks in the development of new 
treatment strategies [98]. WHO actively supports 
capacity building, especially in developing countries, 
fosters partnerships around the world, and works to 
narrow the gap in healthcare inequities through access to 
innovative approaches that take into account different 
health systems, economic and cultural factors. Despite 
the growing consensus for the need for health system 
strengthening, there is little agreement on strategies for 
its implementation [99]. Widely accepted guiding principles 
should be developed with a common language for 
strategy development and communication for the global 
community in general [100] and for NCDs in particular.
Conclusions
NCD management needs to move towards integrated 
care, global strategies and multi-modal systems 
approaches, which will reduce the burden and societal 
impact of NCDs. To this end, we propose that NCDs 
must be considered as the expression of a common group 
of diseases with different risk factors, socio-economic 
determinants and co-morbidities. This will enable the 
application of P4 medicine principles to NCDs, exploiting 
their commonalities, bringing improved global healthcare 
and the reduction of inequities around the world. The 
expected results targeted to better support for patients 
include: (i) better structuring of translational research 
and development for NCDs; (ii) greatly enhanced 
prevention and treatment capabilities; (iii) innovative 
healthcare systems with implementation of follow-up 
procedures directly in the homes of patients; (iv) slowing 
down of health expenditure increase; and (v) new 
interdisciplinary training curricula.
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